Alyeska Investment Group
CTIC

Alyeska Investment Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Alyeska Investment Group’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-196,752
Closed -$767K – 594
2018
Q1 		$767K Buy
+196,752
New +$692K 0.01% 406
2017
Q3 		– Sell
-466,529
Closed -$1.54M – 598
2017
Q2 		$1.54M Buy
+466,529
New +$1.82M 0.01% 369
2016
Q3 		– Sell
-78,949
Closed -$268K – 587
2016
Q2 		$268K Buy
78,949
+1,602
+2% +$7.35K ﹤0.01% 413
2016
Q1 		$411K Buy
77,347
+2,347
+3% +$18.8K ﹤0.01% 367
2015
Q4 		$923K Buy
+75,000
New +$1M 0.01% 342

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Alyeska Investment Group's CTIC Position: Q2 2018 in Review

Alyeska Investment Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2018, closing a stake of 196,752 shares — an estimated $767K sold.

Alyeska Investment Group first reported a position in CTIC in Q4 2015 and held it in 5 quarters. The position peaked at $1.54M in Q2 2017. 83 funds tracked by Wall St. Rank hold CTIC as of Q2 2018.

  • Alyeska Investment Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 196,752 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2018, an estimated $767K.
  • Alyeska Investment Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 5 quarters.
  • Alyeska Investment Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $1.54M in Q2 2017.
  • 83 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2018.

Based on Alyeska Investment Group's 13F filing for Q2 2018, filed 14 Aug 2018.